2025-07-05 - Analysis Report
## RXRX (Recursion Pharmaceuticals Inc) Stock Analysis Report

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging machine learning to discover and develop novel therapeutics.

### 1. Performance vs. S&P 500 (VOO)

*   **RXRX Cumulative Return:** -51.24%
*   **VOO Cumulative Return:** 35.24%
*   **Deviation:**
    *   **Current:** -86.2
    *   **Range (Max: 35.8, Min: -87.9):** Relative Deviation: 1.4

**Analysis:** RXRX has significantly underperformed the S&P 500 (VOO). The current deviation is near the historical low, indicating a substantial divergence in performance. The relative deviation suggests that RXRX's underperformance is at the lower end of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha   | Beta   | Cap(B) |
|------------|--------|--------|---------|--------|--------|
| 2021-2023  | 5.0%   | 73.6%  | -1.0%   | -0.1   | 4.0    |
| 2022-2024  | 0.0%   | 73.6%  | -25.0%  | 0.1    | 2.8    |
| 2023-2025  | 0.0%   | 73.6%  | -48.0%  | 0.1    | 2.1    |

**Analysis:** The company has struggled to deliver competitive returns, which is seen by 0% CAGR the last two analysis. A high MDD indicates significant volatility and risk. The negative Alpha suggests the stock has underperformed relative to its risk, and the Beta values suggest the stock is not very sensitive to market movements, which has been slightly increasing. Also the company's capitalization has been decreasing.

### 2. Recent Stock Price Movements

*   **Current Price:** 5.27
*   **Previous Close:** 5.21
*   **Change:** 1.15%
*   **5-Day Moving Average:** 5.1428
*   **20-Day Moving Average:** 5.1337
*   **60-Day Moving Average:** 4.9423

**Analysis:** The current price is slightly above the moving averages, indicating a short-term upward trend. The positive change from the previous close may indicate the stock is showing some positive momentum.

### 3. Technical Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.3301 (Low Risk)
*   **RSI:** 52.13675039507186
*   **PPO:** 0.233
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (6 shares - Caution - MRI:0.33) (Cash Ratio: 0% on 2025-07-03)
*   **Recent (20-day) Relative Deviation Change:** -2.2 (Negative Trend)
*   **Expected Return (%):** -1845.0%

**Analysis:** The MRI indicates a low-risk environment. The RSI of 52.13675039507186 is neutral, suggesting the stock is neither overbought nor oversold. The Hybrid Signal suggests a "Buy" action but with caution. The negative change in relative deviation over the past 20 days indicates a short-term downward trend in performance compared to VOO. The extremely negative expected return suggests significant underperformance relative to the S&P 500 over a long-term investment horizon. The recent change of 1.15% indicates some volatility, but this is within a normal range.

### 4. Recent News & Significant Events

*   **2025-07-05:** Major business developments, regulatory changes, or market events.
*   **2025-07-03:** Analyst discussions on recent performance and outlook in the context of industry and economic trends.
*   **2025-07-01:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **2025-07-04:** Market experts highlight risks and opportunities, advising investors to monitor news and company announcements.

**Analysis:** Recent news indicates that RXRX has been subject to significant market attention, with volatility and analyst discussions highlighting potential risks and opportunities. Investors should closely monitor news and announcements related to the company.

### 5. Recent Earnings Analysis

| 날짜       | EPS    | 매출       |
|------------|--------|------------|
| 2025-05-05 | -0.50  | 0.01 B$    |
| 2024-11-06 | -0.34  | 0.03 B$    |
| 2024-08-08 | -0.40  | 0.01 B$    |
| 2024-05-09 | -0.39  | 0.01 B$    |
| 2025-05-05 | -0.39  | 0.01 B$    |

**Analysis:** RXRX has consistently reported negative EPS and low revenues. This trend indicates ongoing financial losses.

### 6. Financial Information

Revenue and Profitability:

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-03-31 | $0.01B   | -47.31%       |
| 2024-12-31 | $0.00B   | -183.62%      |
| 2024-09-30 | $0.03B   | 53.69%        |
| 2024-06-30 | $0.01B   | 36.14%        |
| 2024-03-31 | $0.01B   | 17.23%        |

Capital and Profitability:

| Quarter    | Equity   | ROE       |
|------------|----------|-----------|
| 2025-03-31 | $0.93B   | -21.68%   |
| 2024-12-31 | $1.03B   | -17.29%   |
| 2024-09-30 | $0.52B   | -18.27%   |
| 2024-06-30 | $0.58B   | -16.69%   |
| 2024-03-31 | $0.40B   | -22.78%   |

**Analysis:** Revenue has been variable, and profit margins have fluctuated significantly. While some quarters showed positive profit margins, recent trends indicate declining profitability. The Return on Equity (ROE) has been consistently negative, indicating that the company is not generating profits from its equity.

### 7. Overall Analysis

RXRX (Recursion Pharmaceuticals Inc) has significantly underperformed the S&P 500. Key issues include negative EPS, inconsistent revenue, and negative ROE. Recent news indicates volatility and ongoing market attention. Technical indicators suggest a low-risk environment but caution is advised.

**Conclusion:** Given the financial performance and high volatility, investing in RXRX appears highly speculative. Investors should exercise extreme caution and conduct further due diligence before considering an investment. The extremely negative expected return should give investors serious pause.
